World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 16 October 2012
Main ID:  EUCTR2007-004122-24-FI
Date of registration: 04/06/2008
Prospective Registration: Yes
Primary sponsor: Novartis Pharma AG
Public title: An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis.
Scientific title: An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis.
Date of first enrolment: 08/04/2009
Target sample size: 1250
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004122-24
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: yes Other trial design description: Dose-blinded until core study results become available, then open label. If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no  
Phase: 
Countries of recruitment
Belgium Czech Republic Estonia Finland France Germany Greece Hungary
Ireland Netherlands Slovakia Sweden United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Patients should complete the 24 month core study
2. Written informed consent provided prior to participation in extension study
3. Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Premature discontinuation of the study drug during the core study FTY720D2301 due to:
a. An adverse event or serious adverse event or laboratory abnormality, except pregnancy
b. Conditions leading to permanent study drug discontinuation such as macular edema, elevated liver enzymes five times ULN (upper limit of normal), pulmonary function tests below 60% of baseline values. The full description of these exclusion criteria and monitoring guidelines is outlined in Appendix 4: Guidance on Safety Monitoring
2. Chronic disease of the immune system other than MS which may require immunosuppressive treatment
3. History or presence of malignancy
4. Known diagnosis of diabetes mellitus or a blood glucose obtained suspicious for diabetes (= 126 mg/dl or = 7 mmol/L if fasting; = 200 mg/dl or = 11.1 mmol/L if random)
5. Macular edema during the core study
6. Active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests
7. Previous treatment with cladribine, cyclophosphamide or mitoxantrone
8. Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in the past 3 months
9. Any medically unstable condition, that may interfere with the patient’s ability to cooperate and comply with the study procedures, as assessed by the treating physician
10. Any of the following cardiovascular conditions:
a. myocardial infarction within the past 6 months prior to entry in the extension study or with current unstable ischemic heart disease;
b. cardiac failure (Class III, according to New York Heart Association Classification) or any severe cardiac disease as determined by the investigator;
c. arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibulitide, azimilide, dofelitide)
d. history or presence of a third degree AV block
e. proven history of sick sinus syndrome or sino-atrial heart block
f. known history of angina pectoris due to coronary spasm or Raynaud’s phenomenon
11. Any of the following pulmonary conditions:
a. Severe respiratory disease or pulmonary fibrosis diagnosed [during the core study]
b. History of tuberculosis
c. Abnormal chest x-ray or high resolution computer tomography (HRCT) [at selected sites] suggestive of active pulmonary disease in the core study
12. Known history of alcohol abuse, chronic liver disease
13. Current participation in any clinical research study evaluating another investigational drug or therapy
14. Female patients that are nursing (lactating)



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Relapsing-remitting multiple sclerosis.
MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis
Intervention(s)

Product Name: Fingolimod
Product Code: FTY720D
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: fingolimod hydrochloride
CAS Number: 162359-56-0
Current Sponsor code: FTY720
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-

Primary Outcome(s)
Main Objective: Study CFTY720D2301E1 is designed to assess the following properties of FTY720 in patients with relapsing MS:
• To evaluate long-term safety and tolerability
• To evaluate long-term efficacy
Primary end point(s): - Safety:
The safety data from both core and extension studies will be included in the analysis on the safety population. The assessment of safety will be based mainly on the frequency of adverse events and on the incidence of clinically notable laboratory abnormalities. Other safety assessments will include laboratory data summaries, vital signs, bradycardia events, pulmonary function tests, chest x-ray or HRCT, ophthalmic, and ECG data.

- Tolerability:
Tolerability will be assessed by summarizing AEs or abnormal laboratory values by treatment group. No special questionnaires will be offered for assessment of acceptability/tolerability of the study medication.

- Efficacy:
The efficacy variables are annualized relapse rate, time to confirmed disability progression, EDSS score, MSFC score, number of Gd-enhanced T1-weighted lesion, and number of new or newly-enlarged T2 lesions. No statiscal comparisons for the efficacy endpoints will be performed due to the dose changes for patients at their different time points of the study, which makes the statistical comparisons not meaningful.

Please refer to the enclosed Protocol for a detailed description.
Secondary Objective:
Secondary Outcome(s)
Secondary ID(s)
2007-004122-24-SE
CFTY720D2301E1
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history